Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact Us
Stock Information
02186.HK
TradingVolume:736.66
3.87
-0.03  (-0.77%)
Announcement & Circular
10-09
2023
THE COMPANY SUBMITTED NDA FOR PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) TO THE FDA
10-06
2023
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
09-07
2023
THE BREAST CANCER INDICATION OF BAITUOWEI (GOSERELIN MICROSPHERES FOR INJECTION) APPROVED IN CHINA
09-04
2023
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
08-29
2023
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
08-21
2023
SUBMISSION OF NEW DRUG APPLICATION FOR LURBINECTEDIN BY THE GROUP IN MACAO, CHINA
08-17
2023
RYKINDO ENTERED COMMERCIAL OPERATION IN THE UNITED STATE MARKET
08-16
2023
NOTICE OF BOARD MEETING
08-01
2023
ACCEPTANCE OF THE NDA AND PRIORITY REVIEW GRANTED FOR ROTIGOTINE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY03003) BY NMPA IN CHINA
08-01
2023
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
1
2
3
4
5